ArticleCurrent neuropharmacology2010
A systematic, updated review on the antidepressant agomelatine focusing on its melatonergic modulation.
Article in Current neuropharmacology, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed.
- Agomelatine augmentation of sertraline in the treatment of moderate to severe obsessive-compulsive disorder: a randomized double-blinded placebo-controlled clinical trial.BMC psychiatry · 2023Trial
- Agomelatine ameliorates abortion-related alterations in rats: Insights from behavioural, biochemical and histological analyses.Experimental physiology · 2026Article
- Multi-Target-Directed Ligands (MTDLs) as Potential Therapeutic Candidates Targeting Multiple Pathogenic Factor of Alzheimer's Disease.CNS neuroscience & therapeutics · 2026Review
- Dreaming of Better Treatments: Advances in Drug Development for Sleep Medicine and Chronotherapy.Journal of sleep research · 2025Review
- Social Isolation Induces Changes in the Monoaminergic Signalling in the Rat Medial Prefrontal Cortex.Cells · 2024Article
- A multicenter, randomized controlled study on the efficacy of agomelatine in ameliorating anhedonia, reduced motivation, and circadian rhythm disruptions in patients with major depressive disorder (MDD).Annals of general psychiatry · 2023Article
- Sedative-Hypnotic Activity of the Water Extracts ofClocks & sleep · 2022Article
- "Novel Psychopharmacology for Depressive Disorders".Advances in experimental medicine and biology · 2021Review
- Intracellular Signaling Cascades in Bipolar Disorder.Current topics in behavioral neurosciences · 2021Review
- Novel pharmacological treatments for generalized anxiety disorder: Pediatric considerations.Depression and anxiety · 2020Review
- The role of the brain-gut-microbiota axis in psychology: The importance of considering gut microbiota in the development, perpetuation, and treatment of psychological disorders.Brain and behavior · 2019Review
- Understanding the Mechanism of Antidepressant-Related Sexual Dysfunction: Inhibition of Tyrosine Hydroxylase in Dopaminergic Neurons after Treatment with Paroxetine but Not with Agomelatine in Male Rats.Journal of clinical medicine · 2019Article
- What combinations of agomelatine with other antidepressants could be successful during the treatment of major depressive disorder or anxiety disorders in clinical practice?Therapeutic advances in psychopharmacology · 2019Review
- Potentiation of Antidepressant Effects of Agomelatine and Bupropion by Hesperidin in Mice.Neurology research international · 2018Article
- Comparison between Two Linear Supervised Learning Machines' Methods with Principle Component Based Methods for the Spectrofluorimetric Determination of Agomelatine and Its Degradants.Journal of fluorescence · 2017Article
- Agomelatine Protection in an LPS-Induced Psychosis-Relevant Behavior Model.Medical science monitor : international medical journal of experimental and clinical research · 2015Article
- A Comparative Study of Efficacy and Safety of Agomelatine and Escitalopram in Major Depressive Disorder.Journal of clinical and diagnostic research : JCDR · 2015Article
- Agomelatine beyond borders: current evidences of its efficacy in disorders other than major depression.International journal of molecular sciences · 2015Review
- Agomelatine in the treatment of major depressive disorder: an assessment of benefits and risks.Current neuropharmacology · 2014Article
- Melatonin for the treatment of irritable bowel syndrome.World journal of gastroenterology · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo present an updated, comprehensive review on clinical and pre-clinical studies on agomelatine.
methodA MEDLINE, Psycinfo and Web of Science search (1966-May 2009) was performed using the following keywords: agomelatine, melatonin, S20098, efficacy, safety, adverse effect, pharmacokinetic, pharmacodynamic, major depressive disorder, bipolar disorder, Seasonal Affective Disorder (SAD), Alzheimer, ADHD, Generalized Anxiety Disorder (GAD), Panic Disorder (PD), Obsessive-Compulsive Disorder (OCD), anxiety disorders and mood disorder. STUDY COLLECTION AND DATA EXTRACTION: All articles in English identified by the data sources were evaluated. Randomized, controlled clinical trials involving humans were prioritized in the review. The physiological bases of melatonergic transmission were also examined to deepen the clinical comprehension of agomelatine' melatonergic modulation. DATA SYNTHESIS: Agomelatine, a melatonergic analogue drug acting as MT(1)/MT(2) agonist and 5-HT(2C) antagonist, has been reported to be an effective antidepressant therapy.
conclusionsAlthough a bias in properly assessing the "sleep core" of depression may still exist with current screening instruments, therefore making difficult to compare agomelatine' efficacy to other antidepressant ones, comparative studies showed agomelatine to be an intriguing option for depression and, potentially, for other therapeutic targets as well.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.